About Ventyx Biosciences, Inc. - Common Stock (VTYX)
Ventyx Biosciences Inc is a biotechnology company focused on developing innovative therapies for inflammatory and autoimmune diseases. The company harnesses its expertise in the discovery and development of small molecule drug candidates, aiming to address unmet medical needs in various conditions. By leveraging advanced scientific research and clinical insights, Ventyx seeks to bring new treatment options to patients, enhancing the quality of life for those affected by chronic inflammatory disorders. Through its ongoing research and development efforts, Ventyx aims to make significant contributions to the field of medicine. Read More
In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive agreement to acquire Ventyx Biosciences (NASDAQ: VTYX) for approximately $1.2 billion. The all-cash transaction, priced at $14.00 per share, represents
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Ventyx Biosciences, Inc. (NASDAQ: VTYX) to Eli Lilly and Company for $14.00 per share is fair to Ventyx shareholders.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that the Company added two leading experts to their advisory board and provided an update to its ongoing Phase 2 study of VTX2735 in patients with recurrent pericarditis (“RP”).
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York.
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
